Article

Ideal length of androgen ablation for treatment of prostate cancer still debated

Although the observation is awaiting confirmation by more definitive data, it may be that in a select group of radiation-treated prostate cancer patients, 6 months of androgen ablation is as effective as a 3-year course of the adjuvant therapy in terms of cancer-specific survival.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Subscribe Now!
Related Videos
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
2 experts are featured in this series.
Related Content
writing the patient's details | Image Credit: © auremar - stock.adobe.com
June 24th 2025

The C1769 prior authorization puzzle: A billing challenge

Jonathan Rubenstein, MD Mark Painter
"We have received numerous complaints about the PA and predetermination process. We all wish we could answer this differently and definitively," write Jonathan Rubenstein, MD, and Mark Painter.
Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD
June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD
The conversation covers practical, case-based strategies for counseling MSM patients.
Howard B. Goldman, MD, FACS
June 23rd 2025

The future of OAB treatment: Emerging nerve targets and AI may guide therapy

Howard B. Goldman, MD
Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC
June 20th 2025

FDA greenlights phase 1 trial of theranostic radiopharmaceutical for mCRPC

Hannah Clarke
The phase 1 study is set to begin later this year.
CHMP recommends EU approval of darolutamide plus ADT in mHSPC
June 20th 2025

CHMP recommends EU approval of darolutamide plus ADT in mHSPC

Hannah Clarke
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
© 2025 MJH Life Sciences

All rights reserved.